Resources from the same session
3170 - CTONG 1103：Erlotinib versus Gemcitabine plus Cisplatin as Neo-adjuvant Treatment for Stage IIIA –N2 EGFR-mutation Non-small-cell lung cancer (EMERGING): a Randomised Study
Presenter: Wen-Zhao Zhong
Session: Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
4526 - Neoadjuvant nivolumab (N) or nivolumab plus ipilimumab (NI) for resectable non-small cell lung cancer (NSCLC)
Presenter: Tina Cascone
Session: Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies - Invited Discussant LBA48_PR and LBA49
Presenter: Suresh Ramalingam
Session: Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
2875 - A randomized non-comparative phase II study of anti–PD-L1 ATEZOLIZUMAB or chemotherapy as second-line therapy in patients with small cell lung cancer: Results from the IFCT-1603 Trial
Presenter: Jean-Louis Pujol
Session: Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast
Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies - Invited Discussant 1664O and 1363O
Presenter: Johan Vansteenkiste
Session: Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Slides
Webcast
4187 - Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC
Presenter: Corinne Faivre-Finn
Session: Proffered paper session - Non-metastatic NSCLC and other thoracic malignancies
Resources:
Abstract
Slides
Webcast